RTTNews | Aug 4, 2021 09:55AM EDT

09:54 Wednesday, August 4, 2021 (RTTNews.com) - Shares of BeyondSpring Inc. (BYSI) surged over 150% on Wednesday morning after the company reported positive results from a lung cancer treatment trial.

BYSI is currently trading at $24.41, up $14.78 or 153.48%, on the Nasdaq.

BeyondSpring announced positive topline data of DUBLIN-3 registrational trial in plinabulin in combination with docetaxel to treat 2nd and 3rd line NSCLC compared to docetaxel. Plinabulin is a potent antigen presenting cell inducer.

The study met primary endpoint showing statistically significant improvement in overall survival for the combination compared to docetaxel alone.

The study also met key secondary endpoints showing statistically significant improvement for the combination against docetaxel alone in ORR, PFS, and 24- and 36-month OS rates, and significant reduction in incidence of Grade 4 neutropenia.

BeyondSpring plans to seek U.S. FDA and China NMPA approval for plinabulin in combination with docetaxel in NSCLC based on the demonstrated clinical benefit and safety profile.

Read the original article on RTTNews ( https://www.rttnews.com/3215868/beyondspring-surges-150-as-lung-cancer-treatment-trial-meets-primary-endpoints.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved